homepage-top-section

The development programme commences immediately with an aim to introduce the vaccine in 2022, post regulatory approval. This vaccine will be developed with a potential for a multi-valent

The Couvet site is a state-of-the-art manufacturing facility with commercial-scale capacity to produce capsule and tablet dosage forms. For WuXi STA, the Couvet site will be its first

As per the study which was published in the journal Cancer Research, the clinical trial showed positive results of the drug palbociclib in a specific type of triple

The approval for Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) was based on the positive results from SYGMA 1 and SYGMA 2 Phase III trials, which evaluated the efficacy of the

Merck said that the review findings of the clinical trials showed that V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen

Through the expanded agreement, Humanigen will now gain access to manufacturing capacity reserved by the Biomedical Advanced Research and Development Authority (BARDA) for the development of lenzilumab as

The Sputnik V vaccine was registered under the emergency use authorisation procedure based on the results from the Russian Phase III clinical trials on more than 33,000 people.

The rapidly fast-spreading B.1.1.7 lineage, a variant strain of SARS-CoV-2 detected initially in the UK, has ten mutations located in the spike protein. The two firms had earlier

Novartis and GSK have agreed to provide £2.8m ($3.6m) for the Africa Genomic Research Approach for Diversity and Optimizing Therapeutics (GRADIENT) project (Project Africa GRADIENT), over the next